SCHEMBL31111583

SCHEMBL31111583

Brc1cn[nH]c1-c1ccncn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK14 Q16539 6/20 0.51
▸ MAPK10 P53779 1/20 0.51
▸ MAPK9 P45984 2/20 0.48
▸ EGFR P00533 2/20 0.48
▸ PRKACA P17612 2/20 0.48
▸ GSK3B P49841 2/20 0.48
▸ CLK4 Q9HAZ1 2/20 0.48
▸ CSNK1A1 P48729 2/20 0.48
▸ DCLK1 O15075 1/20 0.48
▸ PRKD3 O94806 1/20 0.48
▸ MAP4K4 O95819 1/20 0.48
▸ FLT3 P36888 1/20 0.48
▸ FRK P42685 1/20 0.48
▸ MINK1 Q8N4C8 1/20 0.48
▸ SLK Q9H2G2 1/20 0.48
▸ MAP4K5 Q9Y4K4 1/20 0.48
▸ MAPK13 O15264 2/20 0.39
▸ MAPK12 P53778 2/20 0.39
▸ MAPK11 Q15759 2/20 0.39
▸ RAF1 P04049 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26453218 0.76 TGFBR1 (0.60) MAPK14CSNK1A1TGFBR1TGFBR2ABL2
SCHEMBL30919457 0.76 TGFBR1 (0.60) MAPK14CSNK1A1TGFBR1TGFBR2ABL2
SCHEMBL2814353 0.68 HSP90AA1 (0.52) MAPK14MAPK10MAPK9EGFRPRKACA
SCHEMBL30595872 0.68 HSP90AA1 (0.52) MAPK14MAPK10MAPK9EGFRPRKACA
SCHEMBL29941574 0.68 MAPK10 (1.00) MAPK14MAPK10MAPK9EGFRPRKACA
SCHEMBL14519519 0.68 MAPK14 (0.74) MAPK14MAPK10MAPK9EGFRPRKACA
SCHEMBL27217254 0.67 DYRK1A (0.42) MAPK14PRKACAGSK3BMINK1MAP4K5
SCHEMBL27075642 0.67 CHUK (0.45) MAPK14MAPK10MAPK9GSK3BPRKD3
SCHEMBL13910999 0.66 HSP90AA1 (0.50) MAPK14MAPK10MAPK9EGFRPRKACA
SCHEMBL15500845 0.66 PDPK1 (0.52) MAPK14MAPK10MAPK9EGFRPRKACA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024227104-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BRAF VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. (US) 2024-10-31 — — WO disclosed
Send feedback